FindMyKOL
Clinical trialNCT00629473CompletedPhase 1Interventional

Phase 1 Clinical Trial of NPI-0052 in Patients With Advanced Malignancies

SponsorCelgeneEnrollment86Advanced Cancer
View the registry record on ClinicalTrials.gov

Summary

The lay summary the sponsor registered on ClinicalTrials.gov.

This is a Phase 1 clinical trial examining the safety, pharmacokinetics and pharmacodynamics of escalating doses of the proteasome inhibitor NPI-0052 in patients with advanced malignancies including solid tumors, lymphomas, leukemias and multiple myeloma. By inhibiting proteasomes NPI-0052 prevents the breakdown of proteins involved in signal transduction, which blocks growth and survival in cancer cells.
clinicaltrials.gov ↗

Investigators

The overall officials registered on this study. Names that resolve to a FindMyKOL profile link to it; the rest are shown as registered.

A profile link is shown only when the registered name resolves to a person record with a confident, namesake-checked match; ambiguous names stay unlinked.

Sites

7 registered facilities, with the per-site recruitment status where the registry publishes one. ClinicalTrials.gov does not publish per-site enrollment counts.

Australia
  • Mater Adult Hospital

    South Brisbane, Queensland, Australia

  • the Queen Elizabeth Hospital

    Woodville South, South Australia, Australia

  • Peter Maccallum Cancen Center

    Melbourne, Victoria, Australia

  • the Alfred Hospital

    Melbourne, Victoria, Australia

  • Border Medical Oncology

    Wodonga, Victoria, Australia

  • Sir Charles Gairdner Hospital and University of Western Australia

    Nedlands, Western Australia, Australia

  • Royal Perth Hospital

    Perth, Western Australia, Australia

Site investigator names are published by ClinicalTrials.gov only while a study recruits, so completed studies list sites without them.

Drugs studied

The drug and biological interventions registered on this study, normalized to their RxNorm ingredient where possible.

Dexamethasone →NPI-0052 on Days 1, 4, 8, 11 every 21 daysNPI-0052 on Days 1, 8, 15 every 28 days
Linked drugs open the directory filtered to KOLs working with them.clinicaltrials.gov ↗

Registration & key dates

Registry attributes as recorded on the ClinicalTrials.gov study record.

Start
31 Jul 2007
Primary completion
30 Apr 2013
Completion
30 Apr 2013
Last update posted
22 Nov 2017
Registered enrollment
86
Registry id
NCT00629473
clinicaltrials.gov ↗

Source: ClinicalTrials.gov, via the CTTI AACT database, data as of 24 Aug 2026. Registry facts are shown as registered by the study sponsor; FindMyKOL does not interpret them.